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In the early nineties, pioneering steps were taken in the use of mRNA as a therapeutic tool for 
vaccination. In the following decades, an improved understanding of the mRNA pharmacology, 
together with novel insights in immunology have positioned mRNA-based technologies as 
next-generation vaccines. This review outlines the history and current state-of-the-art in mRNA 
vaccination, while presenting an immunological view on mRNA vaccine development. As such, 
we highlight the challenges in vaccine design, testing and administration, key considerations 
in the design of mRNA-based vaccines and new opportunities that arise when packaging 
mRNA in nanoparticulate vaccines. Finally, we discuss the mRNA self-adjuvant effect as a 
critical, but dichotomous parameter that determines the safety, efficacy and strength of the 
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Highlights 
 mRNA represents an attractive source of antigen in vaccination approaches 
 Both unformulated and nanoparticulate mRNA are used for direct in vivo vaccination 
 Nanoformulation widens the administration and delivery options for mRNA vaccines 
 The self-adjuvant effect of mRNA is a double-edged sword for vaccine efficacy 
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1. Introduction: the first steps in mRNA vaccine development 
The concept of exploiting mRNA as a novel therapeutic drug class has taken off in 1989, when 
a start-up biotech company in San Diego, called Vical Incorporated, published their first 
successes. They demonstrated that mRNA packaged within a liposomal nanoparticle could 
successfully transfect mRNA into a variety of eukaryotic cells [1]. A few months later, Wolff et 
al. ated 
in the muscle of mice. Although this actually served as a control for their liposome-mediated 
delivery, i.m. injection of unformulated mRNA resulted in expression of the encoded protein 
during a couple of days [2]. These preliminary data provided the first evidence that in vitro 
transcribed (IVT) mRNA could deliver the genetic information to produce proteins within living 
tissue. Importantly, this could be achieved without the need of a virus or non-viral vector, which 
countered the existing scepticism about the stability of mRNA in vivo. This encouraged the 
idea that mRNA might offer a valuable and safe alternative to plasmid DNA. Indeed, as the 
mRNA molecules only have to reach the cytosol in order to be translated at the ribosomes, 
they avert the risk of being integrated into the host genome.  
Besides the therapeutic usage of mRNA to transiently replace faulty or missing proteins, it was 
suggested in the early 1990s that mRNA might be useful for the delivery of antigenic 
information to antigen-presenting cells (APCs) [3, 4]. As pioneers, Martinon et al. showed that 
liposomes containing mRNA encoding the influenza virus nucleoprotein elicited virus-specific 
cytotoxic T lymphocytes (CTLs) [3]. In addition to this cellular immunity, Conry et al. 
demonstrated the activation of humoral immune responses, as they confirmed that a 
prophylactic vaccine consisting of mRNA encoding a carcinoembryonic antigen resulted in the 
induction of anti-tumoral antibody responses [4]. After three decades of research, mRNA 
vaccines have reached a new momentum, with many promising candidates entering the 
clinical trial stage. In this review, we will outline the most important fundamental insights that 
have led to our current understanding on how mRNA vaccines should be formulated and 
delivered. We will discuss on how the immunological outcome might vary from one mRNA 
vaccine platform to another, and where there might be room for further improvement to induce 





Figure 1. Pioneering steps and milestones in the development of mRNA-based (cancer) 
vaccines. APC, antigen-presenting cell; PD-1, programmed cell death-1; TLR, Toll like 
receptor, RIG-I, retinoic acid -inducible gene I; IFN, interferon; NSCLC, non small cell lung 
carcinoma; LNP, lipid nanoparticle, IVT, in vitro transcribed; DC, dendritic cell; i.v., intravenous. 
*A few dozen phase I/II trials with mRNA vaccines are ongoing or recruiting patients, 
sponsored by leading biotech companies in the field. 
2. An immunological view on mRNA vaccines 
Shortly after the discovery of the dendritic cell (DC) in 1973 by Ralph Steinman and Zanvil 
Cohn, this cell type was identified as the accessory cell that is required to initiate T cell 
responses [5-7]. DCs are specialized in the uptake, processing and presentation of protein 
antigens to lymphocytes, which links innate and adaptive immune responses. Antigen 
signalling by DCs can either originate from the cytoplasm, which involves the presentation of 
antigenic peptides in major histocompatibility complex (MHC) class I molecules, or alternatively 
from the lysosomes that harbour fragments of endo- or phagocytized antigens which are 
loaded into MHC class II. These MHC complexes, thus loaded either with intracellular antigens 
in MHC-I or extracellular antigens in MHC-II, can then be recognized by the T cell receptor of 
CD8+ T cells or CD4+ T cells, respectively [8]. In addition to this antigen signalling, DCs fulfil 
their essential role in immunity by providing the necessary co-stimulation to trigger the 
activation of antigen-specific T cells. As a result, activated CD8+ CTLs can selectively eliminate 
, such as infected host cells taken over by viruses, and 
. CD4+ T helper cells, for their part, can provide the 
cognate help to further promote and support CTL activity. To achieve humoral immunity, B 
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cells require the recognition of extracellular antigens by the B cell receptor, as well as the 
interaction with activated T helper cells via the MHC class II pathway to enable the production 
of multifunctional, high-affinity antibodies. This knowledge on how DCs steer immune 
responses by specifically engaging different effector cells depending on the source and 
intracellular location of the antigen, has instigated the exploration of (cancer) vaccines, using 
different types of antigens.  
2.1. mRNA as an attractive source of antigen  
One of the key advantages of using antigen-encoding mRNA, is that it provides an easy way 
to evoke MHC-I presentation and elicit CTL responses. In similarity to viral infections, (IVT) 
mRNA allows the transient expression and accumulation of the selected antigens in the 
cytoplasm, which can then efficiently be processed into peptides and loaded in the MHC class 
I pathway, as illustrated in Figure 2. As such, the cytosolic presence of a few mRNA molecules 
can ensure extensive antigen presentation to CTLs, while proteins have to rely on less efficient 
cross-presentation pathways. Interestingly, also the MHC class II pathway can be targeted 
using mRNA as a source of antigen: this either after the secretion and recycling of the mRNA 
expressed proteins, or via direct shuttling of antigens from the cytosol to the lysosomes, e.g., 
promoted by the incorporation of a lysosomal targeting sequence in the mRNA construct [9, 
10]. By comparison with protein-based vaccines, it was recently found that the extended 
antigen availability that can be obtained via mRNA had a profound effect on the magnitude 
and the affinity maturation of antibody responses, resulting in a more durable protection [11-
13].  
Furthermore, mRNA has the advantage of offering a high degree of versatility in the type and 
number of antigenic determinants it encodes. For one, mRNA can code full-length proteins, 
 MHC haplotype. Alternatively, tandem 
constructs can be engineered which connect multiple antigenic epitopes within a single mRNA 
strand. Using this strategy, the company BioNTech AG has developed personalized mRNA-
based cancer vaccines by identifying individual and immunogenic tumor mutations and 
producing on-demand mRNA vaccines encoding these neo-epitopes [14]. A first-in-human trial 
demonstrated the clinical feasibility and safety of this approach for advanced melanoma 
cancers: all vaccinated patients developed CD4+ and CD8+ T cell responses against the 
selected antigens, with some patients showing objective antitumor responses [15]. 
The fact that preparing a new mRNA construct tailored to a specific disease can be done in a 
straightforward and fast way, makes mRNA also an ideal candidate to trigger immunity against 
infectious diseases. These tend to rapidly mutate and therefore require a flexible and rapid 
production of appropriate vaccines that match the circulating viral strains. In this context, 
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prophylactic mRNA vaccines were already considered safe and effective in phase I clinical 
trials for infectious diseases, such as influenza and rabies [16-18]. In small and large animal 
models, mRNA vaccines were able to elicit immunity against emerging infections such as zika, 
ebola and HIV [19-23]. Moreover, by the expression of proteins within the cell, mRNA 
can achieve the production of properly folded and glycosylated antigens, offering solutions to 
the challenging production and limited stability of protein antigens. Moderna Therapeutics 
generated an mRNA vaccine encoding the five different subunits of the pentameric complex 
of the cytomegalovirus (CMV). Together with an mRNA sequence against the CMV 
glycoprotein gB, this multiple-antigenic mRNA vaccine induced potent and durable neutralizing 
antibody titers in immunized mice and non-human primates [24].  
2.2. mRNA as danger signal 
Since the dawn of mRNA in vaccinology, the original model of immune recognition stating that 
-self  proteins, while inducing tolerance against 
 , which was based on a clonal selection theory, was found to be inadequate. In 
1989, Charles Janeway proposed that antigen-presenting cells (APCs) should provide, in 
addition to a suitable antigenic determinant, a second co-stimulatory signal to activate 
lymphocytes. He stated that invading microbes are discriminated as non-self, not by the 
presence of foreign antigens, but through the existence of germline-encoded pattern 
recognition receptors (PRRs) that recognize infectious or microbial components, termed 
pathogen-associated molecular patterns (PAMPs) [25]. A few years later, Polly Matzinger 
elaborated on this concept and stated that APCs do not only respond to exogenous microbial 
signals, but are also activated by danger or alarm signals derived from damaged cells, such 
as heat shock proteins and extracellular nucleic acids [26]. The first real evidence to support 
this infectious non-self model and danger theory emerged in 1996, when Jules Hoffmann 
showed the involvement of Toll-like receptors (TLR) in how Drosophila reacts to pathogenic 
microorganisms. Interestingly, these TLRs had remarkable evolutionary conserved structural 
and functional similarities in mammals [27]. Two years later, the identification of TLR4 as the 
PRR that recognizes bacterial lipopolysaccharide (LPS) in mice by the group of Beutler, truly 
added flesh to the bones of this concept [28].Together with the pioneering work of Ralph 
Steinman in DC biology, these discoveries revolutionized our understanding of how immune 
responses are initiated and regulated.  
While it has long been known s the production of type I interferon 
(IFN), in particular IFN-  IFN- , the exact mechanisms of mRNA  
remained unclear [29]. In the early 2000s, mRNA delivery was shown to trigger an antiviral 
activation state in DCs, which involves the recognition of single-stranded RNA through TLR7 
and TLR8 located in the endosomes [30, 31]. By the formation of secondary RNA structures 
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or through the introduction of contaminants of double-stranded (ds) RNA fragments during the 
IVT mRNA production process, immune activation can be triggered via the endosomal TLR3 
pathway. In addition to these TLRs, dsRNA was shown to activate the cytosolic RNA sensors 
retinoic acid inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 
(MDA5) [32-34].  
The binding of mRNA molecules to these danger sensors leads to downstream signalling via 
specific adaptor molecules (i.e. MyD88 for TLR7/8 and TRIF for TLR3), eventually resulting in 
the production of type I IFN and other pro-inflammatory cytokines (e.g., IL-6 and TNF- . In 
turn, type I IFNs bind autocrine or paracrine receptors, activating the Janus kinase-signal 
transducer activator of transcription (JAK-STAT) pathway, which regulates the gene 
expression of hundreds of proteins involved in antiviral immunity [35, 36]. Hence, these 
signalling pathways coordinate the activation and promotion of distinct innate and adaptive 
immune responses, referred to as the -  
 
 
Figure 2. Mode of action of mRNA to induce adaptive immune responses. 1. Delivery: 
antigen-encoding mRNA should resist degradation by RNases and preferably reach APCs 
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(DCs). mRNA molecules are taken up by receptor-mediated endocytosis and routed through 
the endo-lysosomal compartment. Only a fraction of mRNA escapes the endosomes, 
associates to eIF4E proteins, and binds to the ribosomes, while the largest amount of mRNA 
molecules is degraded. 2. Adjuvant: mRNA is recognized by several PRRs, including 
endosomal TLRs and cytosolic RNA sensors, inducing signalling pathways that regulates the 
production of type I IFNs and other pro-inflammatory cytokines. Type I IFNs act as a double-
edged sword: it initiates the transcription of hundreds of interferon-stimulated genes (ISGs) 
involved in the DC maturation process and directly acts as a third cytokine signal for T cell 
activation, but also promotes antiviral enzymes that enhances mRNA degradation and inhibits 
the mRNA translation process. 3. Antigen presentation: the expression of antigenic proteins 
by the host translation machinery allows the antigen processing and presentation of antigenic 
peptides via the intracellular MHC- in situ
secreted-antigen proteins that can be presented through the MHC-II pathway to helper T cells 
and B cells. 
2.3. The paradigm for mRNA vaccine development 
A number of mRNA vaccine platforms have emerged over the years. The basic structure of 
IVT mRNA closely resembles (i) a protein-
encoding open reading frame (ORF), flanked by (ii) 
at the end sides (iii) a 7- (iv) Figure 
3). The non-coding structural features play essential roles in the pharmacology of mRNA and 
can be individually optimized to modulate the mRNA stability, translation efficiency, and 
immunogenicity [35, 37, 38].  
In 2004, Karikó and colleagues observed, while exposing ex vivo human DCs to mRNA from 
different sources, that these cells tolerated mammalian mRNA, while strong inflammatory 
cytokine responses were detected upon the delivery of mRNA derived from bacteria, necrotic 
mammalian cells and IVT mRNA [39, 40]. Interestingly, they found that the strongly reduced 
immune-modulatory capacity of endogenous mRNA could be attributed to the presence of 
modified nucleotides in the mRNA construct, such as methylated nucleosides or 
pseudouridine. As such, it was established that naturally occurring post-translational 
modifications to the mRNA nucleotides prevent the immune detection of endogenous mRNA, 
which allows the cells to discriminate it from pathological or invading mRNA. This presented 
new opportunities for mRNA development: by incorporating modified nucleosides, mRNA 
transcripts referred to as nucleoside- could now be produced with reduced 
immunostimulatory activitiy, and therefore an improved safety profile. In addition, modified 
nucleosides allowed the design of mRNA vaccines with strongly enhanced stability and 
translation capacity, as they could avoid the direct antiviral pathways that are induced by type 
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IFNs and are programmed to degrade and inhibit invading mRNA [41-45]. For instance, the 
replacement of uridine with pseudouridine in IVT mRNA was found to reduce the activity of 2'-
5'-oligoadenylate synthetase, which regulates the mRNA cleavage by RNase L. In addition, 
lower activities were measured for protein kinase R, an enzyme that is associated with the 
inhibition of the mRNA translation process. In a therapeutic setting, Kormann et al., 
demonstrated that nucleoside-modified mRNA encoding erythropoietin (Epo), in which 25% 
thio-uridine and 25% 5-methylcytidine was incorporated, resulted in five times higher Epo 
levels compared to untreated mice, two weeks after i.m. administration. In contrast, no 
significant changes were detected with unmodified mRNA, which only evoked a substantial 
immune activation [44]. 
Besides the incorporation of modified nucleotides, other approaches have been validated to 
increase the translation capacity and stability of mRNA. One example is the development of 
- . Here, mRNA expression can be strongly increased by 
sequence optimizations in the ORF and UTRs of mRNA, for instance by enriching the GC 
content, or by selecting the UTRs of natural long-lived mRNA molecules [46-50]. Another 
self-  constructs [51, 52]. These are mostly 
derived from alphaviruses, and contain an ORF that is replaced by the antigen of interest 
together with an additional ORF encoding viral replicase. The latter drives the intracellular 
amplification of mRNA, and can therefore significantly increase the antigen expression 
capacity [53]. Already in 1995, Johanning et al. found that the i.m. injection of self-amplifying 
mRNA derived from the Sindbis virus, resulted in a ten-fold increase in protein expression 
levels, which could be maintained much longer (from 2 days up to 10 days) compared to 
nonamplifying mRNA [51]. 
Also, several modifications have been implemented at the end structures of mRNA. Anti-
reverse cap (ARCA) modifications can ensure the correct cap orientation at the 5' end, which 
yields almost complete fractions of mRNA that can efficiently bind the ribosomes [54]. Other 
cap modifications, such as phosphorothioate cap analogs, can further improve the affinity 
towards the eukaryotic translation initiation factor 4E (eIF4E), and increase the resistance 
against the RNA decapping complex [55, 56]. Correlations were found between the elongation 
of the poly(A) tail of mRNA and the duration of expression, and specific modifications 
UTR were reported that can slow-down the decay of the poly(A) tail by deadenylation [57, 58]. 
Also, more exotic approaches have been suggested, such as the generation of circular-
engineered RNAs that render resistance towards exonuclease-mediated degradation [59, 60]. 
Recently, it was demonstrated that the delivery of synthetic polyamine complexes pre-
assembled with mRNA and eIF4E proteins resulted in significantly higher expression 
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efficiencies compared to mRNA alone, which could be attributed to a higher stability and 
recruitment of these complexes to the ribosomes [61]. 
Conversely, by modifying its structure, the potency of mRNA to trigger innate immune 
responses can be further improved, but to the detriment of translation capacity. The company 
CureVac AG found that by stabilizing the mRNA with either a phosphorothioate backbone, or 
by its precipitation with the cationic protein protamine, antigen expression was diminished, but 
stronger immune-stimulating capacities could be obtained [62, 63]. This instigated the 
development of protamine-complexed mRNA molecules to function either solely as an immune 
adjuvant for peptide and protein-based vaccines (i.e. RNAdjuvant®), or in a two-component 
mRNA platform consisting of antigen-encoding mRNA combined with protamine-mRNA 
 (i.e. RNAactive®) [64, 
65]. 
Taken together, these findings resulted in a paradigm of the design of mRNA formulations for 
vaccination. One strategy is to use mRNA which is fully optimized to obtain a strong adjuvant 
improved antigen bio-availability [43, 62]. With respect to vaccination purposes, one should 
complete reduction of the interaction between mRNA molecules and one or multiple virus-
specific PRRs [66]. As such, this might come at the cost of the adjuvant effect of the mRNA 
vaccine. After all, both outcomes are oppositely regulated by type I IFN-induced genes. The 
priority is often given to the translation capacity of mRNA with the idea to improve the antigen 
availability. Yet, from an immunological point-of-view, the innate immune sensing of mRNA, 
which evokes the phenotypic immune profiling and cytokine milieus, is at least equally 
important. Indeed, these innate immune signals will trigger and guide the choice of effector 
 [67]. 
Notwithstanding, the potency of this self-adjuvant effect of mRNA must be weighed against the 
risk of any adverse reaction inherent to it, including inflammation reactions and auto-immune 
events [68]. This key challenge of finding an optimal balance between the translation capacity 
and adjuvanticity of mRNA vaccines, in order to obtain adequate, but safe immunogenicity, will 




Figure 3. Structural features of IVT mRNA. Figure shows the structural elements of IVT 
mRNA. Each of these elements can be optimized and modified in order to modulate the 
stability, translation capacity, and immune-stimulatory profile of mRNA. 
3. mRNA vaccine delivery 
3.1. The in vivo approach 
The first human trials evaluating mRNA delivery were focused on an ex vivo approach, where 
monocyte-derived DCs were transfected with antigen-encoding mRNA and re-infused into the 
patients as a cellular vaccine [69]. Excellent reviews on such mRNA-based DC vaccines can 
be found elsewhere [70, 71]. Over the years, the focus has started to shift towards the direct 
administration of mRNA. In general, the alternative of in vivo approaches that directly target 
mRNA to APCs, holds a number of key benefits to ex vivo generated DC vaccines. First of all, 
the costly and laborious ex vivo steps associated with the isolation and culturing of patient-
specific DCs are avoided. Secondly, the in vivo delivery of mRNA more closely mimics a 
cells and 
non-immune cells can be directly transfected in their natural habitat, which allows the 
immediate innate immune activation and coordinated signalling to adaptive immune cells. 
Moreover, crucial immune events, such as the release of inflammatory cytokines and 
chemokines, that peak within a couple of hours after transfection, can be lost in time and place 
when preparing ex vivo DC vaccines [72, 73]. 
Despite the numerous advantages of mRNA vaccines to target APCs in situ, there are also a 
number of challenging technical hurdles that need to be overcome for mRNA to be successfully 
delivered to their target cells. Independent of the administration route, several evolutionary 
